Group 1: Company Overview - Proris (Shanghai) Pharmaceutical Technology Development Co., Ltd. is a leading data-driven innovative SMO in China, providing one-stop clinical trial site management services to clients including domestic and foreign pharmaceutical companies [2]. - As of September 30, 2023, the company has participated in over 2,800 SMO projects, with 1,741 projects currently in execution, and has expanded its workforce to 4,061 employees, serving over 850 clinical trial institutions across more than 180 cities nationwide [2][3]. Group 2: Financial Performance - In the first three quarters of 2023, the company's net profit exceeded 1 billion CNY for the first time, with a revenue of 5.44 billion CNY, representing a year-on-year increase of 35.53% [2]. - The gross profit margin for the first three quarters of 2023 was 30.29%, with the third quarter showing a gross profit margin of 33.69%, indicating a steady recovery to pre-2019 levels [3][4]. Group 3: Industry Insights - The domestic SMO industry is still in its early development stage, characterized by a fragmented market with several leading companies coexisting with numerous smaller firms. The concentration of the industry is expected to increase, favoring leading SMO companies due to their expanding client resources and institutional coverage [3]. - The company anticipates that regulatory policies in the pharmaceutical sector will benefit SMOs capable of providing innovative project services, further enhancing industry concentration towards leading firms [3]. Group 4: Operational Efficiency - The company is focusing on enhancing its information technology infrastructure and talent development to improve management efficiency and solidify its leading position in the SMO industry [3][4]. - The implementation of an internal information management system has improved the execution of clinical trial outsourcing services, enabling rapid responses and timely feedback during project management [4].

证券代码：301257 证券简称：普蕊斯 公告编号：2023-065 关于公司股东权益变动计划期限届满的公告 股东平潭弘润盈科新材料创业投资合伙企业（有限合伙）、张晶保证向本公 司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）于 2023 年 5 月 19 日披露了《关于公司股东减持股份预披露公告》（公告编号 2023-028）， 持有公司股份 2,250,000 股（占公告时公司总股本比例 3.6900%）的股东平潭弘 润盈科新材料创业投资合伙企业（有限合伙）（以下简称"弘润盈科"）计划自 权益变动计划公告发布之日起 3 个交易日后的 6 个月内以大宗交易方式或/及集 中竞价交易方式减持本公司股份不超过 2,245,400 股（占公告时公司总股本比例 3.6825%）；持有公司股份 2,250,000 股（占公告时公司总股本比例 3.6900%）的 股东张晶，计划自权益变动计划公告发布之日起 3 个交易日后的 6 个月内以大宗 交易方式或/及集中竞价交易方式减 ...

Financial Performance - The net profit for the first three quarters of 2023 exceeded 100 million CNY, with a revenue of 544 million CNY, representing a year-on-year increase of 35.53% [3] - As of September 30, 2023, the company has participated in over 2,800 SMO projects, with 1,741 projects currently in execution [3] Business Operations - The company has expanded its employee base to 4,061, serving over 850 clinical trial institutions and covering more than 1,300 institutions across over 180 cities in China [3] - The company aims to enhance its business expansion, accelerate information technology development, and improve organizational capabilities to solidify its leading position in the SMO industry [3] Competitive Advantages - The company is positioned in the first tier of the SMO industry, leveraging its early entry and professional service capabilities to become a qualified supplier for major pharmaceutical companies [4] - It has established comprehensive standard operating procedures (SOP) for clinical trials, ensuring stable and reliable service delivery [4] - The management team possesses over 10 years of industry experience, enhancing the reliability and stability of clinical trial execution [4] Future Vision - The long-term vision is to become a service provider that utilizes big data and innovative models to efficiently advance clinical trial execution and support new drug research [4] - The company primarily serves multinational pharmaceutical companies, domestic innovative drug companies, and CROs [4] Recruitment and Training - As of September 30, 2023, the company has nearly 3,900 business personnel, with recruitment plans dynamically matched to business needs [5] - The training cycle for new clinical research coordinators (CRC) is generally three months, incorporating online and offline training methods [5] - A robust personnel management and training system has been established to mitigate high turnover risks in the SMO industry [5]

Group 1: Company Overview - Prusis is a leading data-driven innovative SMO (Site Management Organization) in China, providing comprehensive clinical trial site management services to domestic and international pharmaceutical companies [2] - As of September 30, 2023, the company has participated in over 2,800 SMO projects, with 1,741 projects currently in execution [3] - The company has expanded its workforce to 4,061 employees and serves over 850 clinical trial institutions, covering more than 1,300 clinical trial sites across over 180 cities in China [3] Group 2: Financial Performance - In the first three quarters of 2023, the company's net profit exceeded 1 billion RMB for the first time, with a revenue of 5.44 billion RMB, representing a year-on-year increase of 35.53% [2] - The company has strengthened its business coverage and enriched project experience, contributing to significant growth in revenue and profitability [2] Group 3: Market Trends and Strategy - The SMO industry is experiencing a shift towards head SMOs, with clients increasingly recognizing the importance of executing clinical trials rather than merely monitoring them [3] - The company is enhancing its refined management practices and maintaining stable pricing, which has positively impacted revenue growth [3] Group 4: Operational Management - The company employs a milestone-based revenue recognition method, with specific payment nodes tied to project progress, ensuring clarity in revenue confirmation [4][5] - To address potential management challenges due to workforce expansion, the company is focusing on refined management and information technology systems to improve operational efficiency [6] Group 5: Future Plans - The company plans to continue expanding its SMO business and accelerate information technology development, enhancing management efficiency and service capabilities [6][7] - There are intentions to explore overseas business opportunities and diversify service offerings when suitable opportunities arise [7]

关于普蕊斯（上海）医药科技开发股份有限公司 2023 年第二次临时股东大会的法律意见书 北京国枫（上海）律师事务所 国枫律股字［2023］B0034 号 致：普蕊斯（上海）医药科技开发股份有限公司（以下称"贵公司"或"普蕊斯"） 北京国枫（上海）律师事务所（以下称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2023 年第二次临时股东大会（以下称"本次会议"）。 根据《中华人民共和国公司法》（以下称"《公司法》"）、《中华人民共和国 证券法》（以下称"《证券法》"）、中国证券监督管理委员会发布的《上市公司股 东大会规则》（以下称"《股东大会规则》"）、《律师事务所从事证券法律业务管 理办法》（以下称"《从业办法》"）、《律师事务所证券法律业务执业规则（试行）》 （以下称"《执业规则》"）及《普蕊斯（上海）医药科技开发股份有限公司章程》 （以下称"《公司章程》"）等有关规定，就本次会议的召集与召开程序、召集人资 格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1. 本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员资格、 ...

2023 年第二次临时股东大会决议公告 证券代码：301257 证券简称：普蕊斯 公告编号：2023-064 普蕊斯（上海）医药科技开发股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次会议采取现场表决与网络投票相结合的方式。 2、本次股东大会不存在否决提案的情况。 3、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议召开时间：2023 年 11 月 16 日（星期四）14：30 （2）网络投票时间：通过深交所交易系统进行网络投票的具体时间为：2023 年 11 月 16 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深交所互联网投票系统 投票的具体时间为 2023 年 11 月 16 日 9:15-15:00 期间的任意时间。 2、召开地点：上海市黄浦区广东路 500 号世界贸易大厦 23 楼大会议室 6、本次会议的召集、召开符合《公司法》《上市公司股东大会规则》《深 圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门规章、规范性 ...

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 编号：2023-024 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 □现场参观 券商策略会 □其他 广发基金 南方基金 招商基金 宝盈基金 博时基金 景顺长城基金 银河基金 万家基金 华夏基金 长城基金 平安基金 华宝基金 参与单位 银华基金 信达澳亚基金 富荣基金 恒生前海基金 名称及人员 前海开源基金 淳厚基金 摩根华鑫基金 安信基金 姓名 中国五矿 兴银理财 华能贵诚信托 泰康资管 玄元投资 华夏未来资管 山证国际资管 浙商证券 光大证券 国金证券 开源证券 东北证券 等共56家机构72人 2023年11月3日、2023 年11月6日 时间 2023年11月8日-11 月10日 地点 上海 深圳 上市公司接 董事会秘书 赖小龙 待人员姓名 ...

3、类型：股份有限公司（上市、自然人投资或控股） 证券代码:301257 证券简称:普蕊斯 公告编号:2023—063 普蕊斯（上海）医药科技开发股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日召开公司第三届董事会第五次会议，审议通过了《关于变更公司注册 资本、修订<公司章程>并办理工商变更登记及备案的议案》，具体内容详见公司 于 2023 年 10 月 30 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于变更公司注册资本、修订<公司章程>并办理工商变更登记及备案的公告》。 近日，经上海市市场监督管理局核准，公司完成了相关工商变更登记和《公 司章程》备案手续，并取得了换发的《营业执照》，现将变更后的登记情况公告 如下： 一、变更之后的《营业执照》的基本信息 1、名称：普蕊斯（上海）医药科技开发股份有限公司 2、统一社会信用代码：913100000625748002 4、法定代表人 ...

普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日召开了第三届董事会第五次会议和第三届监事会第五次会议，审议通 过了《关于公司 2022 年限制性股票激励计划首次授予部分第一个解除限售期解 除限售条件成就的议案》，公司已按照《普蕊斯（上海）医药科技开发股份有限 公司 2022 年限制性股票激励计划》（以下简称"《激励计划》"）的相关规定为 77 名激励对象持有的 39 万股限制性股票办理解除限售相关手续，现将有关事项 说明如下： 证券代码：301257 证券简称：普蕊斯 公告编号：2023-062 普蕊斯(上海)医药科技开发股份有限公司 关于 2022 年限制性股票激励计划首次授予部分第一个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、2022 年限制性股票激励计划首次授予部分第一个解除限售期符合解除限 售条件的激励对象共计 77 人，实际解除限售的数量为 39 万股，占公司目前股 本总额的 0.64%。 2、本次解除限售的限制性股票的上市流通日为 20 ...

Financial Performance - The company's net profit for the first three quarters of 2023 exceeded 1 billion CNY, representing a year-on-year increase of 35.53% [3] - Revenue for the same period reached 5.44 billion CNY, indicating significant growth [3] - The gross profit margin for the first three quarters was 30.29%, with a third-quarter margin of 33.69%, reflecting a recovery to pre-2019 levels [5] Business Expansion - As of September 30, 2023, the company participated in over 2,800 SMO projects, with 1,741 projects currently in execution [3] - The workforce increased to 4,061 employees, with nearly 3,900 in business roles, enhancing operational capacity [6] - The company aims to strengthen its market position by expanding its service capabilities and increasing the number of clinical trial sites across 180 cities [3] Market Trends - The domestic innovative drug market is expected to continue growing, driven by supportive national policies and advancements in drug development technologies [4] - The SMO industry is experiencing a trend towards consolidation, with leading firms expanding their client resources and operational scale [4] - The company is focusing on high-quality development, targeting mid-to-high-end pharmaceutical clients who are less affected by capital market fluctuations [4] Strategic Initiatives - The company plans to enhance its information technology infrastructure and talent management to improve operational efficiency [3] - There is a commitment to maintaining stable pricing and improving project management systems to drive revenue growth [4] - Future recruitment will be dynamically aligned with business needs, leveraging data analytics for resource allocation [6]